curriculum vitae milind javle, m.d. · curriculum vitae milind javle, m.d. present title and...

CURRICULUM VITAE

Milind Javle, M.D.

PRESENT TITLE AND AFFILIATION Primary Appointment

Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment N/A

CITIZENSHIP United States

HOME ADDRESS 2007 Swift Blvd Houston, TX 77030 Cell: 281-630-5662

OFFICE ADDRESS The University of Texas MD Anderson Cancer Center 1515 Holcombe Blvd Unit Number: 426 Houston, TX 77030 Room Number: FC10.3026 Phone: 713-792-2828 Fax: 713-745-9926 Email: [email protected]

EDUCATION Degree-Granting Education

Grant Medical College, University of Bombay, India, Bombay, India, MD, 1991, Medicine Postgraduate Training

Clinical Internship, Internal Medicine, State University of New York (SUNY) Buffalo, Buffalo, NY, 1993-1994 Clinical Residency, Internal Medicine, SUNY Buffalo, Buffalo, NY, 1994-1995 Clinical Fellowship, Medical Oncology, Roswell Park Cancer Institute, Buffalo, NY, 1995-1998

CREDENTIALS Board Certification

Board Certification in Internal Medicine (ABIM), 1/1995-1/2019, Recertification Date: 1997 Medical Oncology, 5/2009-12/2019

Licensures Active

Medical, TX, M5776, 2007 Inactive

N/A

Milind Javle, M.D.

of 24

EXPERIENCE/SERVICE Academic Appointments

Medical Oncologist and Internist, Cancer Treatment Services, Geneseo, NY, 10/1998-9/2001 Assistant Professor, Roswell Park Cancer Institute, Buffalo, NY, 10/2001-12/2006 Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 1/2007-present

Administrative Appointments/Responsibilities N/A

Other Appointments/Responsibilities Reviewer, Data Monitoring and Safety Committee, Ohio State University Cancer Center, Columbus, OH, 2004-2007 Guidelines Panel Member, National Comprehensive Cancer Network (NCCN), n/a, 2005-2008 Scientific Program Committee Member, American Society of Clinical Oncology, n/a, 2007-present Senate Member, The University of Texas MD Anderson Cancer Center, Houston, 2009-present Associate Member, The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, TX, 9/2009-8/2010 Vice Chair, The Cholangiocarcinoma Foundation - Clinical Science Advisory Board, Salt Lake City, UT, 2014-present Director, The Cholangiocarcinoma Foundation - International Cholangiocarcinoma Research Network, Salt Lake City, 2014-present

Endowed Positions N/A

Consultantships N/A

Military or Other Governmental Service N/A

Institutional Committee Activities N/A

HONORS AND AWARDS Scientific Program Committee Track Leader, ASCO, 2008-2009 Three-year appointment award, The University of Texas MD Anderson Cancer Center, 2008-2011 Listing in 'Guide to America's Top Physicians', 2010-2011, 2010-2011, 2011-2012, 2012-2013 Tenure Track Appointment, The University of Texas MD Anderson Cancer Center, 2011-present Best Teaching Attending: 2005-6; Medical Oncology Fellows, Roswell Park Cancer Institute Early promotion in Internal Medicine, SUNY Buffalo Grant from AACR for research and travel to AACR/ASCO workshop in methods in Clinical Cancer Research, Park City Utah, 8/17-23, 1996, AACR Honors in Pharmacology, University of Bombay 1979 Physician of the Month: Hospice Buffalo: July 2004

RESEARCH Grants and Contracts

Funded Principal Investigator, 0.12 months, Ph2 single arm study of BGJ398 in patients with advanced or metastatic cholangio with FGFR2 gene fusions or other FGFR genetic alterations who failed

Milind Javle, M.D.

of 24

or are intolerant to platinum-based chemo, 2014-0372, Novartis, 4/15/2014-4/14/2019, $347,781 ($347,781/year) Principal Investigator, Phase II randomized study of ACP-196 with gemcitabine + nab-paclitaxel for advanced pancreatic cancer, Acerta Pharma, 6/2015-6/2018 Co-Investigator, 0.12 months, Molecular Epidemiology of Gallbladder Cancer, 2017-00054812, SINF, PI - Pant, Shubham, 9/1/2017-8/31/2019, $100,000 ($50,000/year) Principal Investigator, 0.6 months, Genomic/Immunological Heterogeneity of Intrahepatic Cholangiocarcinoma Research Network, CA180064, Department of Defense (DOD), 10/1/2019-9/30/2023, $1,411,312 ($915,758/year)

Pending Investigator, 0.12 months, Phase II trial of BTK inhibitor ACP - 196 with gemcitabine & abrarane for pancreatic cancer, The University of Texas MD Anderson Cancer Center, 3/2015-present

Other N/A

Completed Co-Investigator, 0.12 months, Cellular and Molecular Mechanisms of Gastrointestinal Cancers, 5P01CA130821-04, NIH/NCI, PI - Lopa Mishra, 9/1/2012-8/31/2014, $1,310,391 Principal Investigator, 0.12 months, A Phase I/Randomized Phase II Study of Gemcitabine + Erlotinib + MK-0646; Gemcitabine + MK-0646 and Gemcitabine + Erlotinib for Patients with Advanced Pancreatic Cancer, IISP33337, Merk and Company, 5/30/2013-5/29/2018 Co-Investigator, 0.6 months, Identification of a genetic signature of survival in patients with potentially curable pancreatic adenocarcinoma, IRG Katz Identification Gen, MDACC Institutional Research Grant, PI - Matthew Katz, 8/1/2013-7/31/2014 Principal Investigator, Targeting BAP1 in intrahepatic cholangiocarcinoma, The Cholangiocarcinoma Foundation, 7/1/2014-6/30/2016, $50,000 ($50,000/year)

Not Funded Principal Investigator, 0.6 months, Evaluating a novel bruton tyrosine kinase inhibitor in pancreatic cancer, Pancreatic Cancer Action Network, 7/1/2016-6/30/2019, $1,987,934 Principal Investigator, 1.2 months, Novel immunotherapy with Pembrolizumab and bruton tyrosine kinase inhibitor for familial pancreatic cancer, NIH/NCI, 9/1/2016-8/31/2020, $2,845,051 Principal Investigator, 5%, Association Between Somatic Genetic Mutations and Immune Biomarker Expression in Biliary Tract Cancer, Hope Foundation, 1/1/2017-9/30/2020, $62,500 ($50,000/year) Principal Investigator, 15%, Leveraging NQO1 bioactivatable drug for tumor selective use of PARPi, RP180119, Un of TX Southwestern Med Ctr Dallas, 3/1/2018-2/28/2021, $418,800 ($397,860/year) Co-Investigator, 0.24 months, Devising effective treatment for PDAC by co-targeting tumor cells and the tumor microenvironment, RP190026, Cancer Prevention & Research Institute of Texas (CPRIT), 2/1/2019-1/31/2023 ($285,000/year)

Protocols Funded

Principal Investigator, RAD001 + Erlotinib for Advanced Gemcitabine-Refractory Pancreatic Cancer. Phase II study, 2007-0666, 2007-2010, Novartis OSI Pharmaceuticals Principal Investigator, MK-0646 with Gemcitabine; MK-0646 with Gemcitabine and Erlotinib or Gemcitabine and Erlotinib. A randomized phase II study for pancreatic cancer, 2007-0910, 2007-present, $1,314,527, Merck

Milind Javle, M.D.

of 24

Principal Investigator, Relevant Safety Study and Pharmacokinetic Determination of Cholecystokinin Type A Receptor VP16-GAL4-WPRE Integrated Systemic Amplifier Bcl12 Interacting Killer (BikDD nanoparticle) in CD1 Mice, 01-08-00531, 2008-2009, NCI Spore Principal Investigator, Preclinical study of SOM230B and Akt inhibition, CSOM230BUS11T, 2009-2010, Novartis Principal Investigator, (Local) Phase I Study of MEK inhibitor Array 162-111, 2009-0956, 2010-2013, Array Biopharma Principal Investigator, A phase II multicenter, single arm study of oral BGJ398 in adult patients with advanced or metastatic cholangiocarcinoma with FGFR2 gene fusions or other FGFR genetic alterations who failed or are intolerant to platinum-based chemotherapy (CBGJ398X2204), 2014-0372, 2014-2019, $502,954, Novartis Principal Investigator, Olaparib Monotherapy in Metastatic Pancreatic Cancer, 2015-0690, 2016-present, $274,205, Astra Zeneca Principal Investigator, Phase II study of olaparib for pancreatic cancer with BRCAness phenotype, 2015-0503, 2016-present, $494,912, Astra Zeneca Principal Investigator, Randomized study of ACP-196, 2015-0273, 2016-present, Acerta Principal Investigator, Single-arm, phase II proof of concept study of IDO-1 inhibitor epacadostat in combination with pembrolizumab in advanced pancreatic cancer with chromosomal instability/ homologous recombination repair deficiency (HRD), Contract Pending, 2016-present, Incyte Principal Investigator, A Multicenter, Double-Blind Randomized Placebo-Controlled Study of Varlitinib Plus Capecitabine Versus Placebo Plus Capecitabine in Patients with Advanced or Metastatic Biliary Tract Cancer as Second-Line Systemic Therapy, 2017-0481, 2017-2020 ($155,915/year), ASLAN Pharmaceuticals Principal Investigator, A Pivotal Trial of ARQ 087 in Subjects, 54445, PI - Milnd Javle, 2017-2020 ($180,732/year), Basilea Pharmaceutica Ltd Principal Investigator, A Phase II Study of Gemcitabine, Cisplatin, and Abraxana in Advanced Biliary Ca, 2014-0524, 2018-2020 ($92,940/year), CELGENE Principal Investigator, A Phase II Study of siG12D LODER in Combination in Patients with Unresectable Locally Advanced Pancreatic Cancer (NCT01676259), 2018-0847, 2018-2020 ($57,531/year), Silenseed Ltrd Principal Investigator, 2019-0320 Phase 3 MULTICENTER, OPEN LABEL, RANDOMIZED, CONTROLLED STUDY OF THE ORAL INFIGRANTIB VERSUS GEMCITABINE WITH CISPLATIN IN SUBJECTS WITH ADNVACED/ METASTATIC OR INOPERABLE CHOLANGIOCARCINOMA WITH FGFR2 GENE FUSION, 57082, PI - MILIND JAVLE, 2019-present, QED THERAPUTICS

Unfunded N/A

Patents and Technology Licenses Patents

N/A Technology Licenses

N/A

Grant Reviewer/Service on Study Sections Recovery Act Challenge Grant, NIH, mail reviewer, 2009 Lastgarten Foundation, NIH, Reviewer, 2013-2014 The University of Texas MD Anderson Cancer Center, NIH, IRG Reviewer, 2013-present

Milind Javle, M.D.

of 24

The Cholangiocarcinoma Foundation, NIH, reviewer, 2014-present

PUBLICATIONS Peer-Reviewed Original Research Articles

1. Javle M, Raghavan D. Systemic Therapy for Invasive Bladder Cancer. Cancer Control 3(6):501-506, 11/1996. PMID: 10764508.

2. Javle M, Raghavan D. Total androgen blockade for prostate cancer: the end does not justify the means. Cancer Treat Res 88:201-210, 1996. PMID: 9239481.

3. Raghavan D, Koczwara B, Javle M. Evolving strategies of cytotoxic chemotherapy for advanced prostate cancer. Eur J Cancer 33(4):566-574, 4/1997. PMID: 9274436.

4. Javle M, Raghavan D. Radiotherapy and chemotherapy for invasive bladder cancer. Cancer Surv 31:149-60, 1998. PMID: 15281322.

5. Creaven P, Javle M, Raghavan D. Taxol based chemotherapy for non-small cell lung cancer. Advances in Oncology 15:18-24, 1999.

6. Creaven PJ, Slocum HK,Toth K, Pendyala L, Smith P, Litwin A, Intengan M, Javle MM, Ramnath N, Loewen G, Rustum YM. Modulation of 5-Fluorouracil by Irinotecan in advanced solid tumors-A pilot study. Intl J Cancer suppl 13:94, 2002.

7. Bhagat V, Javle M, Geradts J. Carcinoma of the esophagus with mixed basaloid squamous and glandular differentiation: a distinct histological presentation. Int J Gastrointest Cancer 34(2-3):139-142, 2003. PMID: 15361648.

8. Chu QD, Khushalani N, Javle MM, Douglass HO Jr, Gibbs JF. Should adjuvant therapy remain the standard of care for patients with resected adenocarcinoma of the pancreas? Ann Surg Oncol 10:539-545, 2003.

9. Varma GN, Winston JS, Hill HC, Gibbs JF, Proulx GM, McGrath BE, Javle MM. Unusual locations of involvement by malignancies: Case 3. Gastric signet ring carcinoma presenting as a diffuse thigh mass. J Clin Oncol 21(17):3371-3373, 2003. PMID: 12947076.

10. Wilkinson NW, Black JD, Roukhadze E, Driscoll D, Smiley S, Hoshi H, Geradts J, Javle M, Brattain M. Epidermal growth factor receptor expression correlates with histologic grade in resected esophageal adenocarcinoma. J Gastrointest Surg 8(4):448-53, May-Jun, 5/2004. PMID: 15120370.

11. Gowda A, Goel R, Berdzik J, Leichman CG,Javle M. Hypersensitivity Reactions to oxaliplatin: incidence and management. Oncology (Williston Park) 18(13):1671-5; discussion 1676, 1680, 1683-4, 11/2004. PMID: 15648298.

12. Javle MM, Tan D, Yu J, LeVea CM, Li F, Kuvshinoff BW, Gibbs JF. Nuclear survivin expression predicts poor outcome in cholangiocarcinoma. Hepatogastroenterology 51(60):1653-1657, Nov-Dec, 11/2004. PMID: 15532797.

13. James TA, Sheldon DG, Rajput A, Kuvshinoff BW, Javle MM, Nava HR, Smith JL, Gibbs JF. Risk factors associated with earlier age of onset in familial pancreatic carcinoma. Cancer 101(12):2722-2726, 12/2004. PMID: 15534880.

14. Chadha MK, LeVea C, Javle M, Kuvshinoff B, Vijaykumar R, Iyer R. Anaplastic pancreatic carcinoma. A case report and review of literature. JOP 5(6):512-515, 2004. PMID: 15536293.

15. Iyer R, Wilkinson N, Demmy T, Javle M. Controversies in the multimodality management of locally advanced esophageal cancer: evidence-based review of surgery alone and combined-modality therapy. Ann Surg Oncol 11:665-673, 2004.

16. Shaukat A, Mortazavi A, Demmy T, Nava H, Wilkinson N, Yang G, Kepner J, Javle M. Should preoperative, post-chemoradiotherapy endoscopy be routine for esophageal cancer patients? Dis Esophagus 17:129-135, 2004.

17. Palesty JA, Wang W, Javle MM, Yang GY. Side effects of therapy: case 3. Gastric cancer after radiotherapy of pediatric Hodgkin's disease. J Clin Oncol 22(12):2507-2509, 2004. PMID: 15197215.

18. Mortazavi A, Shaukat A, Othman E, Kepner JL, Fakih MG, Kuvshinoff BW, Smith JL, Javle MM. Postoperative computed tomography scan surveillance for patients with stage II and III colorectal cancer: worthy of further study? Am J Clin Oncol 28(1):30-35, 2/2005. PMID: 15685032.

19. Li F, Yang J, Ramnath N, Javle MM, Tan D. Nuclear or cytoplasmic expression of survivin: What is the significance? Int J Cancer 114(4):509-512, 4/2005. PMCID: PMC2829944.

Milind Javle, M.D.

of 24

20. Javle M. Salvage Esophagectomy for Recurrent Esophageal Adenocarcinoma: A Viable Option for Chemotherapy Responders. Hem Onc. Today, 6/2005.

21. Bahadur S, Shaukat A, Gibbs J, Litwin A, Nava H, Melnyk M, Javle M. Cisplatin and Gemcitabine for small cell carcinoma of the gall bladder. Am J Clin Oncol 28(4):425-426, 8/2005. PMID: 16062088.

22. Fakih MG, Creaven PJ, Ramnath N, Trump D, Javle M, Strychor S, Repinski TV, Zamboni BA, Schwarz JK, French RA, Zamboni WC. Phase I and pharmacokinetic study of weekly docetaxel, cisplatin, and daily capecitabine in patients with advanced solid tumors. Clin Cancer Res 11(16):5942-9, 8/2005. PMID: 16115937.

23. Ramnath N, Khushalani, N, Toth K, Litwin A, Intengen M, Slocum HK, Pendyala L, Smith P, Stewart C, Hoffman J, Javle M, Berdzik J, Creaven PJ, Rustum YM. S-Phase Modulation by Irinotecan: Pilot Studies in Advanced Solid Tumors. Cancer Chemotherapy and Pharmacology 56(5):447-454, 11/2005.

24. Watwe V, Javle M, Lawrence D, Groth J, Iyer R, El-Hajjar D, Geradts J. Cyclooxygenase-2 (COX-2) levels before and after chemotherapy: a study in rectal cancer. Am J Clin Oncol 28(6):560-4, 12/2005. PMID: 16317264.

25. Ailawadhi S, Shenoy S, Sham R, Javle M. Transarterial chemoembolization in a patient with recurrent hepatocellular carcinoma and portal vein thrombosis: a case report and review of the literature. Am J Clin Oncol 28(6):638-9, 12/2005. PMID: 16317281.

26. Tripp P, Malhotra HK, Javle M, Shaukat A, Russo R, De Boer S, Podgorsak M, Nava H, Yang GY. Cardiac function after chemoradiation for esophageal cancer: comparison of heart dose-volume histogram parameters to multiple gated acquisition scan changes. Dis Esophagus 18(6):400-405, 2005. PMID: 16336612.

27. Nallapareddy S, Wilding GE, Yang G, Iyer R, Javle M. Chemoradiation is a Tolerable Therapy for Older Adults with Esophageal Cancer. Anticancer Res 25(4):3055-3060, Jul-Aug, 2005. PMID: 16080565.

28. Khoury T, Chadha K, Javle M, Donohue K, Levea C, Iyer R, Okada H, Nagase H, Tan D. Expression of Intestinal Trefoil Factor (TFF-3) in hepatocellular carcinoma. Int J Gastrointest Cancer 35(3):171-177, 2005. PMID: 16110118.

29. Watwe V, Farrell CD, Javle M. Muir-Torre Syndrome associated with Turcot syndrome. Internet Journal of Gastroenterology 3(2):online, 2005.

30. Chadha MK, Kuvshinoff BW, Javle MM. Neoadjuvant Therapy for Gastric Cancer. Oncology (Williston Park) 19(9):1219-1227, 2005. PMID: 16255136.

31. Beer TM, Javle M, Lam GN, Henner WD, Wong A, Trump DL. Pharmacokinetics and Tolerability of a Single Dose of DN-101, a New Formulation of Calcitriol, in Patients with Cancer. Clin Cancer Res 11(21):7794-7799, 2005. PMID: 16278401.

32. Chadha KS, Hernandez-Ilizaliturri FJ, Javle M. Primary esophageal lymphoma: case series and review of the literature. Dig Dis Sci 51(1):77-83, 1/2006. PMID: 16416216.

33. Bdair FM, Graham SP, Smith PF, Javle MM. Gemcitabine and acute myocardial infarction--a case report. Angiology 57(3):367-71, May-Jun, 5/2006. PMID: 16703198.

34. Chadha KS, Khoury T, Yu J, Black JD, Gibbs JF, Kuvshinoff BW, Tan D, Brattain MG, Javle MM. Activated Akt and Erk expression and survival after surgery in pancreatic carcinoma. Ann Surg Oncol 13(7):933-9, 2006. PMID: 16715446.

35. Javle M, Yu J, Khoury T, Chadha KC, Iyer RV, Foster J, Kuvshinoff BW, Gibbs JF, Geradts J, Black JD, Brattain MG. Akt expression may predict favorable prognosis in cholangiocarcinoma. J Gastroenterol Hepatol. 21(11):1744-51, 2006.

36. Bhagat V, Javle M, Yu J, Agrawal A, Gibbs JF, Kuvshinoff B, Nava E, Iyer R. Combined Hepatocholangiocarcinoma: case-series and review of literature. Int J Gastrointest Cancer 37(1):27-34, 2006. PMID: 17290078.

37. Ajani J, Bekaii-Saab T, D'Amico TA, Fuchs C, Gibson MK, Goldberg M, Hayman JA, Ilson DH, Javle M, Kelley S, Kurtz RC, Locker GY, Meropol NJ, Minsky BD, Orringer MB, Osarogiagbon RU, Posey JA, Roth J, Sasson AR, Swisher SG, Wood DE, Yen Y. Esophageal Cancer Clinical Practice Guidelines. J Natl Compr Canc Netw 4(4):328-347, 2006. PMID: 16569387.

38. Leichman L, Lawrence D, Leichmen C, Hava H, Nava E, Proulx G, Clark K, Khushalani N, Berdzik J, Greco W, Smith P, Creaven P, Kepner J, Javle M, Pendyala L. Expression of

Milind Javle, M.D.

of 24

genes related to the activity of oxaliplatin, 5-fluorouracil and radiation: characterization and exploratory analysis with survival. J Chemother 18(5):514-24, 2006.

39. Ajani J, Bekaii-Saab T, D'Amico TA, Fuchs C, Gibson MK, Goldberg M, Hayman JA, Ilson DH, Javle M, Kelley S, Kurtz RC, Locker GY, Meropol NJ, Minsky BD, Orringer MB, Osarogiagbon RU, Posey JA, Roth J, Sasson AR, Swisher SG, Wood DE, Yen Y. Gastric Cancer Clinical Practice Guidelines. J Natl Compr Canc Netw 4(4):350-366, 2006. PMID: 16569388.

40. Javle M, Nwogu CE, Donohue KA, Iyer RV, Brady WE, Khemka SV, Smith JL, Demmy TL, Yang GY, Nava HR. Management of locoregional stage esophageal cancer: A single center experience. Dis. Of Esophagus 19(2):78-83, 2006.

41. Javle M, Ailawadhi S, Yang GY, Nwogu CE, Schiff MD, Nava HR. Palliation of malignant dysphagia in esophageal cancer: a literature-based review. J Support Oncol. 4(8):365-73, 379, 2006.

42. Chadha KS, Hernandez-Illizaliturri FJ, Javle M. Primary esophageal lymphoma: Case series and review of the literature. Dig Dis Sci. 51:77-83, 2006.

43. Jayaprakash V, Menezes RJ, Javle MM, McCann SE, Baker JA, Reid ME, Natarajan N, Moysich KB. Regular aspirin use and esophageal cancer risk. Int J Cancer 119(1):202-207, 2006. PMID: 16450404.

44. Javle MM, Cao S, Durrani FA, Pendyala L, Lawrence DD, Smith PF, Creaven PJ, Noel DC, Iyer RV, Rustum YM. Celecoxib and mucosal protection: translation from an animal model to a phase I clinical trial of celecoxib, irinotecan, and 5-fluorouracil. Clin Cancer Res 13(3):965-71, 2/2007. PMID: 17289892.

45. Foster J, Black J, LeVea C, Khoury T, Kuvshinoff B, Javle M, Gibbs JF. COX-2 expression in hepatocellular carcinoma is an initiation event, while EGF receptor expression with downstream pathway activation is a prognostic predictor of survival. Ann Surg Oncol 14(2):752-8, 2/2007. e-Pub 12/2006. PMID: 17146741.

46. Foster JM, Hoshi H, Gibbs JF, Iyer R, Javle M, Chu Q, Kuvshinoff B. Gallbladder cancer: Defining the indications for primary radical resection and radical re-resection. Ann Surg Oncol 14(2):833-40, 2/2007. e-Pub 11/2006. PMID: 17103074.

47. Javle M, Shah P, Yu J, Bhagat V, Litwin A, Iyer R, Gibbs J. Cystic pancreatic tumors (CPT): Predictors of malignant behavior. J Surg Oncol 95(3):221-228, 3/2007. PMID: 17323335.

48. Chiappori AA, Eckhardt SG, Bukowski R, Sullivan DM, Ikeda M, Yano Y, Yamada-Sawada T, Kambayashi Y, Tanaka K, Javle MM, Mekhail T, O'bryant CL, Creaven PJ. A phase I pharmacokinetic and pharmacodynamic study of s-3304, a novel matrix metalloproteinase inhibitor, in patients with advanced and refractory solid tumors. Clin Cancer Res 133(7):2091-9, 4/2007. PMID: 17404091.

49. Agrawal S, Kuvshinoff BW, Khoury T, Yu J, Javle MM, LeVea C, Groth J, Coignet LJ, Gibbs JF. CD24 Expression is an Independent Prognostic Marker in Cholangiocarcinoma. J Gastrointest Surg 11(4):445-51, 4/2007. PMCID: PMC1852393.

50. Beer TM, Javle MM, Ryan CW, Garzotto M, Lam GN, Wong A, Henner WD, Johnson CS, Trump DL. Phase I study of weekly DN-101, a new formulation of calcitriol, in patients with cancer. Cancer Chemother Pharmacol 59(5):581-7, 4/2007. e-Pub 10/2006. PMID: 17066293.

51. Ailawadhi S, Nagase H, Khoury T, Yu J, Tan D, Black J, Brattain M, Javle M. Intestinal trefoil factor (TFF-3) and extracellular signal-regulated kinase (ERK) in cholangiocarcinoma. Hepatogastroenterology 54(77):1339-44, Jul-Aug, 7/2007. PMID: 17708250.

52. Javle M, Yang GY. Review: neoadjuvant chemoradiotherapy and chemotherapy improve survival in operable esophageal cancer. ACP J Club 147(1):19, Jul-Aug, 7/2007. PMID: 17608384.

53. Patt YZ, Lee FC, Liebmann JE, Diamandidis D, Eckhardt SG, Javle M, Justice GR, Keiser W, Salvatore JR, Bexon A, Lin E. Capecitabine plus 3-weekly irinotecan (XELIRI regimen) as first-line chemotherapy for metastatic colorectal cancer: phase II trial results. Am J Clin Oncol 30(4):350-7, 8/2007. PMID: 17762434.

54. Pande A, Lombardo J, Spangenthal E, Javle M. Hypertension secondary to anti-angiogenic therapy: experience with bevacizumab. Anticancer Res 27(5B):3465-70, Sep-Oct, 9/2007. PMID: 17972502.

Milind Javle, M.D.

of 24

55. Donthireddy KR, Ailawadhi S, Nasser E, Schiff MD, Nwogu CE, Nava HR, Javle MM. Malignant gastroparesis: pathogenesis and management of an underrecognized disorder. J Support Oncol 5(8):355-63, 9/2007. PMID: 17944143.

56. Iyer RV, Gibbs J, Kuvshinoff B, Fakih M, Kepner J, Soehnlein N, Lawrence D, Javle MM. A phase II study of gemcitabine and capecitabine in advanced cholangiocarcinoma and carcinoma of the gallbladder: a single-institution prospective study. Ann Surg Oncol 14(11):3202-9, 11/2007. e-Pub 8/2007. PMID: 17705089.

57. Javle MM, Gibbs JF, Iwata KK, Pak Y, Rutledge P, Yu J, Black JD, Tan D, Khoury T. Epithelial-Mesenchymal Transition (EMT) and Activated Extracellular Signal-regulated Kinase (p-Erk) in Surgically Resected Pancreatic Cancer. Ann Surg Oncol 14(12):3527-33, 12/2007. e-Pub 9/2007. PMID: 17879119.

58. OConnor BM, Chadha MK, Pande A, Lombardo JC, Nwogu CE, Nava HR, Yang G, Javle MM. Concurrent oxaliplatin, 5-fluouracil and radiation for esophageal cancer. Cancer Journal 13(2):119, 2007.

59. Pande AU, Iyer RV, Rani A, Maddipatla S, Yang GY, Nwogu CE, Black JD, Levea CM, Javle MM. Epidermal growth factor receptor-directed therapy in esophageal cancer. Oncology 73(5-6):281-9, 2007. e-Pub 5/2008. PMID: 18477853.

60. Donthireddy KR, Schiff MD, Ailawadhi S, Javle M. Malignant Gastroparesis: An under-recognized entity. J of Supportive Oncology 5(8):355, 2007.

61. Javle M, Pande A, Iyer R, Yang G, LeVea C, Wilding G, Black J, Nava H, Nwogu C. Pilot study of gefitinib, oxaliplatin, and radiotherapy for esophageal adenocarcinoma: tissue effect predicts clinical response. Am J Clin Oncol 31(4):329-34, 8/2008. PMID: 18845990.

62. Ettinger DS, Agulnik M, Cristea M, Eaton K, Fidias PM, Gockerman JP, Hameed O, Handorf C, Harris EI, Jacobs CD, Javle M, Khushalani NI, Kvols L, Lenzi R, Lewis NL, Rashid A, Saltz L, Shulman LN, Zager JS, Zhen W. Occult primary. J Natl Compr Canc Netw 6(10):1026-60, 11/2008. PMID: 19176200.

63. Javle MM, Yang G, Nwogu CE, Wilding GE, O'Malley L, Vinjamaram S, Schiff MD, Nava HR, LeVea C, Clark KR, Prey JD, Smith PF, Pendyala L. Capecitabine, oxaliplatin and radiotherapy: a phase IB neoadjuvant study for esophageal cancer with gene expression analysis. Cancer Invest 27(2):193-200, 2/2009. PMID: 19235592.

64. Brell JM, Krishnamurthi SS, Javle M, Saltzman J, Wollner I, Pelley R, Dowlati A, Kantharaj BN, Schluchter MD, Rath L, Ivy SP, Remick SC. A multi-center phase II study of oxaliplatin, irinotecan, and capecitabine in advanced gastric/gastroesophageal junction carcinoma. Cancer Chemother Pharmacol 63(5):851-7, 4/2009. e-Pub 8/2008. PMID: 18670776.

65. Javle M, Yu J, Garrett C, Pande A, Kuvshinoff B, Litwin A, Phelan J, Gibbs J, Iyer R. Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: a phase II study. British Journal of Cancer 100(12):1842-5, 6/2009. e-Pub 6/2009. PMCID: PMC2714236.

66. Chadha MK, Lombardo J, Mashtare T, Wilding GE, Litwin A, Raczyk C, Gibbs JF, Kuvshinoff B, Javle MM, Iyer RV. High-dose octreotide acetate for management of gastroenteropancreatic neuroendocrine tumors. Anticancer Res 10(10):4127-30, 10/2009. PMID: 19846960.

67. Haque W, Crane CH, Krishnan S, Delclos ME, Javle M, Garrett CR, Wolff RA, Das P. Reirradiation to the abdomen for gastrointestinal malignancies. Radiat Oncol 4:55, 2009. e-Pub 11/2009. PMCID: PMC2787526.

68. Chadha MK, Litwin A, Levea C, Iyer R, Yang G, Javle M, Gibbs JF. Surgical resection after TNFerade therapy for locally advanced pancreatic cancer. JOP 10(5):535-8, 2009. e-Pub 9/2009. PMID: 19734632.

69. Javle M, Hsueh CT. Updates in Gastrointestinal Oncology - insights from the 2008 44th annual meeting of the American Society of Clinical Oncology. J Hematol Oncol 2:9, 2009. e-Pub 2/2009. PMCID: PMC2654905.

70. Okazaki T, Javle M, Tanaka M, Abbruzzese JL, Li D. Single nucleotide polymorphisms of gemcitabine metabolic genes and pancreatic cancer survival and drug toxicity. Clin Cancer Res 16(1):320-9, 1/2010. e-Pub 12/2009. PMCID: PMC2802655.

71. May KS, Khushalani NI, Chandrasekhar R, Wilding GE, Iyer RV, Ma WW, Flaherty L, Russo RC, Fakih M, Kuvshinoff BW, Gibbs JF, Javle MM, Yang GY. Analysis of Clinical and

Milind Javle, M.D.

of 24

Dosimetric Factors Associated with Change in Renal Function in Patients with Gastrointestinal Malignancies After Chemoradiation to the Abdomen. Int J Radiat Oncol Biol Phys 76(4):1193-8, 3/2010. e-Pub 6/2009. PMID: 19540051.

72. Hassan MM, Curley SA, Li D, Kaseb A, Davila M, Abdalla EK, Javle M, Moghazy DM, Lozano RD, Abbruzzese JL, Vauthey JN. Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma. Cancer 116(8):1938-46, 4/2010. e-Pub 2/2010. PMID: 20166205.

73. Dong X, Javle M, Hess KR, Shroff R, Abbruzzese JL, Li D. Insulin-like Growth Factor Axis Gene Polymorphisms and Clinical Outcomes in Pancreatic Cancer. National Institute of Health - Gastroenterology 139(2):464-73, 473.e1-3, 8/2010. e-Pub 4/2010. PMCID: PMC2910789.

74. Huang TC, Kar S, Javle M. Personalized therapy for pancreatic cancer: Myth or reality in 2010? J Gastrointest Oncol 1(1):24-33, 9/2010. PMCID: PMC3397566.

75. Atiq M, Javle M, Dang S, Lee JH. Cholangiocarcinoma: an endoscopist's perspective. Expert Rev Gastroenterol Hepatol 4(5):601-11, 10/2010. PMID: 20932145.

76. Tanaka M, Javle M, Dong X, Eng C, Abbruzzese JL, Li D. Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer. National Institute of Health 116(22):5325-35, 11/2010. PMCID: PMC2966859.

77. Lo SS, Khorana AA, Javle M, Simon S, Kiefer G, Rajasenan K, Wang H, Hantel A, Shayne M, Hwang J, Schmotzer A, Ramanathan RK. A phase II study of weekly docetaxel in combination with capecitabine in advanced gastric and gastroesophageal adenocarcinomas. Oncology 78(2):125-9, 2010. e-Pub 4/2010. PMID: 20389134.

78. Pan JJ, Javle M, Thinn MM, Hsueh CT, Hsueh CT. Critical appraisal of the role of sorafenib in the management of hepatocellular carcinoma. Hepat Med 2:147-55, 2010. e-Pub 11/2010. PMCID: PMC3846497.

79. Javle MM, Shroff RT, Xiong H, Varadhachary GA, Fogelman D, Reddy SA, Davis D, Zhang Y, Wolff RA, Abbruzzese JL. Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies. BMC Cancer 10:368, 2010. e-Pub 7/2010. PMCID: PMC2910694.

80. Javle M, Hsueh CT. Recent advances in gastrointestinal oncology--updates and insights from the 2009 annual meeting of the American Society of Clinical Oncology. J Hematol Oncol 3:11, 2010. e-Pub 3/2010. PMCID: PMC2856525.

81. Fogelman DR, Wolff RA, Kopetz S, Javle M, Bradley C, Mok I, Cabanillas F, Abbruzzese JL. Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer. Anticancer Res 31(4):1417-20, 4/2011. PMID: 21508395.

82. Raju RP, Jaganmohan SR, Ross WA, Davila ML, Javle M, Raju GS, Lee JH. Optimum Palliation of Inoperable Hilar Cholangiocarcinoma: Comparative Assessment of the Efficacy of Plastic and Self-Expanding Metal Stents. Dig Dis Sci 56(5):1557-64, 5/2011. e-Pub 1/2011. PMID: 21222156.

83. Golan T, Javle M. Targeting the insulin growth factor pathway in gastrointestinal cancers. Oncology (Williston Park) 25(6):518-26, 529, 5/2011. PMID: 21717907.

84. El-Rayes BF, Philip PA, Sarkar FH, Shields AF, Ferris AM, Hess K, Kaseb AO, Javle MM, Varadhachary GR, Wolff RA, Abbruzzese JL. A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer. Invest New Drugs 29(4):694-9, 8/2011. e-Pub 1/2010. PMID: 20107864.

85. Crane CH, Varadhachary GR, Yordy JS, Staerkel GA, Javle MM, Safran H, Haque W, Hobbs BD, Krishnan S, Fleming JB, Das P, Lee JE, Abbruzzese JL, Wolff RA. Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression. J Clin Oncol 29(22):3037-43, 8/2011. e-Pub 6/2011. PMCID: PMC3157965.

86. Eckmann KR, Patel DK, Landgraf A, Slade JH, Lin E, Kaur H, Loyer E, Weatherly JM, Javle M. Chemotherapy outcomes for the treatment of unresectable intrahepatic and hilar cholangiocarcinoma: a retrospective analysis. Gastrointest Cancer Res 4(5-6):155-60, 9/2011. PMCID: PMC3269144.

Milind Javle, M.D.

of 24

87. Javle M, Curtin NJ. The role of PARP in DNA repair and its therapeutic exploitation. Br J Cancer 105(8):1114-22, 10/2011. PMCID: PMC3208503.

88. Skinner HD, Sharp HJ, Kaseb AO, Javle MM, Vauthey JN, Abdalla EK, Delclos ME, Das P, Crane CH, Krishnan S. Radiation treatment outcomes for unresectable hepatocellular carcinoma. Acta Oncol 50(8):1191-8, 11/2011. e-Pub 7/2011. PMID: 21793641.

89. Javle M, Curtin NJ. The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy. Ther Adv Med Oncol 3(6):257-67, 11/2011. PMCID: PMC3210467.

90. Singal AK, Ross WA, Guturu P, Varadhachary GR, Javle M, Jaganmohan SR, Raju RP, Fleming JB, Raju GS, Kuo YF, Lee JH. Self-expanding metal stents for biliary drainage in patients with resectable pancreatic cancer: single-center experience with 79 cases. Dig Dis Sci 56(12):3678-84, 12/2011. e-Pub 7/2011. PMID: 21750930.

91. Katz MH, Wolff R, Crane CH, Varadhachary G, Javle M, Lin E, Evans DB, Lee JE, Fleming JB, Pisters PW. Survival and Quality of Life of Patients with Resected Pancreatic Adenocarcinoma Treated with Adjuvant Interferon-Based Chemoradiation: A Phase II Trial. Ann Surg Oncol 18(13):3615-22, 12/2011. e-Pub 6/2011. PMID: 21701927.

92. Hecht JR, Farrell JJ, Senzer N, Nemunaitis J, Rosemurgy A, Chung T, Hanna N, Chang KJ, Javle M, Posner M, Waxman I, Reid A, Erickson R, Canto M, Chak A, Blatner G, Kovacevic M, Thornton M. EUS or percutaneously guided intratumoral TNFerade biologic with 5-fluorouracil and radiotherapy for first-line treatment of locally advanced pancreatic cancer: a phase I/II study. Gastrointest Endosc 75(2):332-8, 2/2012. PMID: 22248601.

93. Subbiah IM, Subbiah V, Tsimberidou AM, Naing A, Kaseb AO, Javle M, Fu S, Hong DS, Piha-Paul S, Wheler JJ, Hess KR, Janku F, Falchook GS, Wolff RA, Kurzrock R. Targeted Therapy of Advanced Gallbladder Cancer and Cholangiocarcinoma with Aggressive Biology: Eliciting Early Response Signals from Phase 1 trials. Oncotarget 4(1):153-62, 1/2013. e-Pub 1/2013. PMCID: PMC3702215.

94. Subbiah IM, Subbiah V, Tsimberidou AM, Naing A, Kaseb AO, Javle M, Fu S, Hong DS, Piha-Paul S, Wheler JJ, Hess KR, Janku F, Falchook GS, Wolff RA, Kurzrock R. Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trials. Oncotarget 4(1):156-65, 1/2013. PMCID: PMC3702215.

95. Atiq M, Bhutani MS, Ross WA, Raju GS, Gong Y, Tamm EP, Javle M, Wang X, Lee JH. Role of endoscopic ultrasonography in evaluation of metastatic lesions to the pancreas: a tertiary cancer center experience. Pancreas 42(3):516-23, 4/2013. PMID: 23211369.

96. Khalil MA, Qiao W, Carlson P, George B, Javle M, Overman M, Varadhachary G, Wolff RA, Abbruzzese JL, Fogelman DR. The addition of erlotinib to gemcitabine and cisplatin does not appear to improve median survival in metastatic pancreatic cancer. Invest New Drugs. e-Pub 5/2013. PMID: 23645398.

97. Kunkeaw N, Jeon SH, Lee K, Johnson BH, Tanasanvimon S, Javle M, Pairojkul C, Chamgramol Y, Wongfieng W, Gong B, Leelayuwat C, Lee YS. Cell death/proliferation roles for nc886, a non-coding RNA, in the protein kinase R pathway in cholangiocarcinoma. Oncogene 32(32):3722-31, 8/2013. e-Pub 8/2012. PMID: 22926522.

98. Das P, Abboud MT, Haque W, Javle M, Kaseb A, Curley SA, Vauthey JN, Aloia TA, Beddar AS, Delclos ME, Krishnan S, Crane CH. Gastric bleeding after radiation therapy for intrahepatic cholangiocarcinoma. Pract Radiat Oncol 3(4):344-8, Oct-Dec, 10/2013. e-Pub 12/2012. PMID: 24674408.

99. Tanasanvimon S, Garg N, Viswanathan C, Truong M, Kaur H, Kee BK, Sahin IH, Javle MM, Garrett CR. High prevalence of recurrent thrombosis in subsets of cancer patients with isolated gonadal vein thrombosis: a single center retrospective study. Thromb Res 133(2):154-7, 2/2014. e-Pub 10/2013. PMID: 24331209.

100. Roa I, de Toro G, Schalper K, de Aretxabala X, Churi C, Javle M. Overexpression of the HER2/neu gene: a new therapeutic possibility for patients with advanced gallbladder cancer? Gastrointest Cancer Res 7(2):42-8, 3/2014. PMCID: PMC4007675.

101. Javle M, Rashid A, Churi C, Kar S, Zuo M, Eterovic AK, Nogueras-Gonzalez GM, Janku F, Shroff RT, Aloia TA, Vauthey JN, Curley S, Mills G, Roa I. Molecular Characterization of Gallbladder Cancer using Somatic Mutation Profiling. Hum Pathol 45(4):701-8, 4/2014. e-Pub 11/2013. PMID: 24508317.

Milind Javle, M.D.

of 24

102. Van Loon K, Espinoza AM, Fogelman DR, Wolff RA, Javle MM, Iyer RV, Picozzi VJ, Martin LK, Bekaii-Saab T, Tempero MA, Foster NR, Kim GP, Ko AH. Should combination chemotherapy serve as the backbone in clinical trials of advanced pancreatic cancer? A pooled analysis of phase II trials of gemcitabine-containing doublets plus bevacizumab. Pancreas 43(3):343-9, 4/2014. PMCID: PMC3955845.

103. Koay EJ, Truty MJ, Cristini V, Thomas RM, Chen R, Chatterjee D, Kang Y, Bhosale PR, Tamm EP, Crane CH, Javle M, Katz MH, Gottumukkala VN, Rozner MA, Shen H, Lee JE, Wang H, Chen Y, Plunkett W, Abbruzzese JL, Wolff RA, Varadhachary GR, Ferrari M, Fleming JB. Transport properties of pancreatic cancer describe gemcitabine delivery and response. J Clin Invest 124(4):1525-36, 4/2014. e-Pub 3/2014. PMCID: PMC3973100.

104. Liu C, Karam R, Zhou Y, Su F, Ji Y, Li G, Xu G, Lu L, Wang C, Song M, Zhu J, Wang Y, Zhao Y, Foo WC, Zuo M, Valasek MA, Javle M, Wilkinson MF, Lu Y. The UPF1 RNA Surveillance Gene is Commonly Mutated in Pancreatic Adenosquamous Carcinoma. Nat Med 20(6):596-8, 6/2014. e-Pub 5/2014. PMCID: PMC4048332.

105. Huguet F, Mukherjee S, Javle M. Locally advanced pancreatic cancer: the role of definitive chemoradiotherapy. Clin Oncol (R Coll Radiol) 26(9):560-8, 9/2014. e-Pub 7/2014. PMID: 25001636.

106. Fogelman DR, Holmes H, Mohammed K, Katz MH, Prado CM, Lieffers J, Garg N, Varadhachary GR, Shroff R, Overman MJ, Garrett C, Wolff RA, Javle M. Does IGFR1 inhibition result in increased muscle mass loss in patients undergoing treatment for pancreatic cancer? J Cachexia Sarcopenia Muscle 5(4):307-313, 12/2014. e-Pub 4/2014. PMID: 24740741.

107. Anwar S, Tan W, Yu J, Hutson A, Javle M, Iyer R. Quality-of-life (QoL) as a predictive biomarker in patients with advanced pancreatic cancer (APC) receiving chemotherapy: results from a prospective multicenter phase 2 trial. J Gastrointest Oncol 5(6):433-439, 12/2014. PMCID: PMC4226818.

108. Javle M, Smyth EC, Chau I. Ramucirumab: Successfully Targeting Angiogenesis in Gastric Cancer. Clin Cancer Res 20(23):5875-81, 12/2014. e-Pub 10/2014. PMID: 25281695.

109. Rogers JE, Law L, Nguyen VD, Qiao W, Javle MM, Kaseb A, Shroff RT. Second-line systemic treatment for advanced cholangiocarcinoma. J Gastrointest Oncol 5(6):408-413, 12/2014. PMCID: PMC4226829.

110. Javle M, Li Y, Tan D, Dong X, Chang P, Kar S, Li D. Biomarkers of TGF-β signaling pathway and prognosis of pancreatic cancer. PLoS One 9(1):e85942, 2014. e-Pub 1/2014. PMCID: PMC3896410.

111. Koay EJ, Baio FE, Ondari A, Truty MJ, Cristini V, Thomas RM, Chen R, Chatterjee D, Kang Y, Zhang J, Court L, Bhosale PR, Tamm EP, Qayyum A, Crane CH, Javle M, Katz MH, Gottumukkala VN, Rozner MA, Shen H, Lee JE, Wang H, Chen Y, Plunkett W, Abbruzzese JL, Wolff RA, Maitra A, Ferrari M, Varadhachary GR, Fleming JB. Intra-tumoral heterogeneity of gemcitabine delivery and mass transport in human pancreatic cancer. Phys Biol 11(6):065002, 2014. e-Pub 11/2014. PMID: 25427073.

112. Churi CR, Shroff R, Wang Y, Rashid A, Kang HC, Weatherly J, Zuo M, Zinner R, Hong D, Meric-Bernstam F, Janku F, Crane CH, Mishra L, Vauthey JN, Wolff RA, Mills G, Javle M. Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications. PLoS One 9(12):e115383, 2014. e-Pub 12/2014. PMCID: PMC4275227.

113. Zuo M, Rashid A, Churi C, Vauthey JN, Chang P, Li Y, Hung MC, Li D, Javle M. Novel therapeutic strategy targeting the Hedgehog signalling and mTOR pathways in biliary tract cancer. Br J Cancer 112(6):1042-51, 3/2015. e-Pub 3/2015. PMCID: PMC4366884.

114. Shindoh J, de Aretxabala X, Aloia TA, Roa JC, Roa I, Zimmitti G, Javle M, Conrad C, Maru DM, Aoki T, Vigano L, Ribero D, Kokudo N, Capussotti L, Vauthey JN. Tumor Location Is a Strong Predictor of Tumor Progression and Survival in T2 Gallbladder Cancer: An International Multicenter Study. Ann Surg 261(4):733-9, 4/2015. e-Pub 5/2014. PMID: 24854451.

115. Zuo M, Li C, Lin J, Javle M. LLL12, a novel small inhibitor targeting STAT3 for hepatocellular carcinoma therapy. Oncotarget 6(13):10940-9, 5/2015. PMCID: PMC4484430.

116. Chadha AS, Kocak-Uzel E, Das P, Minsky BD, Delclos ME, Mahmood U, Guha S, Ahmad M, Varadhachary GR, Javle M, Katz MH, Fleming JB, Wolff RA, Crane CH, Krishnan S.

Milind Javle, M.D.

of 24

Paraneoplastic thrombocytosis independently predicts poor prognosis in patients with locally advanced pancreatic cancer. Acta Oncol 54(7):971-8, 7/2015. e-Pub 1/2015. PMID: 25608822.

117. Aloia TA, Járufe N, Javle M, Maithel SK, Roa JC, Adsay V, Coimbra FJ, Jarnagin WR. Gallbladder Cancer: expert consensus statement. HPB (Oxford) 17(8):681-90, 8/2015. PMCID: PMC4527853.

118. Fogelman D, Sugar EA, Oliver G, Shah N, Klein A, Alewine C, Wang H, Javle M, Shroff R, Wolff RA, Abbruzzese JL, Laheru D, Diaz LA. Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma. Cancer Chemother Pharmacol 76(3):489-98, 9/2015. e-Pub 7/2015. PMID: 26126726.

119. Roland CL, Katz MH, Tzeng CW, Lin H, Varadhachary GR, Shroff R, Javle M, Fogelman D, Wolff RA, Vauthey JN, Crane CH, Lee JE, Fleming JB. The Addition of Postoperative Chemotherapy is Associated with Improved Survival in Patients with Pancreatic Cancer Treated with Preoperative Therapy. Ann Surg Oncol 22 Suppl 3:1221-8, 12/2015. e-Pub 9/2015. PMID: 26350371.

120. Javle M, Churi C, Kang HC, Shroff R, Janku F, Surapaneni R, Zuo M, Barrera C, Alshamsi H, Krishnan S, Mishra L, Wolff RA, Kaseb AO, Thomas MB, Siegel AB. HER2/neu-directed therapy for biliary tract cancer. J Hematol Oncol 8:58, 2015. e-Pub 5/2015. PMCID: PMC4469402.

121. Roa I, de Toro G, Fernández F, Game A, Muñoz S, de Aretxabala X, Javle M. Inactivation of tumor suppressor gene pten in early and advanced gallbladder cancer. Diagn Pathol 10:148, 2015. e-Pub 8/2015. PMCID: PMC4546176.

122. Tao R, Krishnan S, Bhosale PR, Javle MM, Aloia TA, Shroff RT, Kaseb AO, Bishop AJ, Swanick CW, Koay EJ, Thames HD, Hong TS, Das P, Crane CH. Ablative Radiotherapy Doses Lead to a Substantial Prolongation of Survival in Patients With Inoperable Intrahepatic Cholangiocarcinoma: A Retrospective Dose Response Analysis. J Clin Oncol 34(3):219-26, 1/2016. e-Pub 10/2015. PMID: 26503201.

123. Hong TS, Wo JY, Yeap BY, Ben-Josef E, McDonnell EI, Blaszkowsky LS, Kwak EL, Allen JN, Clark JW, Goyal L, Murphy JE, Javle MM, Wolfgang JA, Drapek LC, Arellano RS, Mamon HJ, Mullen JT, Yoon SS, Tanabe KK, Ferrone CR, Ryan DP, DeLaney TF, Crane CH, Zhu AX. Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. J Clin Oncol 34(5):460-8, 2/2016. e-Pub 12/2015. PMID: 26668346.

124. Chen J, Yao ZX, Chen JS, Gi YJ, Muñoz NM, Kundra S, Herlong HF, Jeong YS, Goltsov A, Ohshiro K, Mistry NA, Zhang J, Su X, Choufani S, Mitra A, Li S, Mishra B, White J, Rashid A, Wang AY, Javle M, Davila M, Michaely P, Weksberg R, Hofstetter WL, Finegold MJ, Shay JW, Machida K, Tsukamoto H, Mishra L. TGF-β/β2-spectrin/CTCF-regulated tumor suppression in human stem cell disorder Beckwith-Wiedemann syndrome. J Clin Invest 126(2):527-42, 2/2016. e-Pub 1/2016. PMCID: PMC4731168.

125. Javle M, Golan T, Maitra A. Changing the course of pancreatic cancer - Focus on recent translational advances. Cancer Treat Rev 44:17-25, 3/2016. e-Pub 1/2016. PMID: 26924195.

126. Krishnan S, Chadha AS, Suh Y, Chen HC, Rao A, Das P, Minsky BD, Mahmood U, Delclos ME, Sawakuchi GO, Beddar S, Katz MH, Fleming JB, Javle MM, Varadhachary GR, Wolff RA, Crane CH. Focal Radiation Therapy Dose Escalation Improves Overall Survival in Locally Advanced Pancreatic Cancer Patients Receiving Induction Chemotherapy and Consolidative Chemoradiation. Int J Radiat Oncol Biol Phys 94(4):755-65, 3/2016. e-Pub 12/2015. PMCID: PMC4792191.

127. Roa I, Garcia H, Game A, de Toro G, de Aretxabala X, Javle M. Somatic Mutations of PI3K in Early and Advanced Gallbladder Cancer: Further Options for an Orphan Cancer. J Mol Diagn. e-Pub 3/2016. PMID: 26947513.

128. Tjensvoll K, Lapin M, Buhl T, Oltedal S, Steen-Ottosen Berry K, Gilje B, Søreide JA, Javle M, Nordgård O, Smaaland R. Clinical relevance of circulating KRAS mutated DNA in plasma from patients with advanced pancreatic cancer. Mol Oncol 10(4):635-43, 4/2016. e-Pub 12/2015. PMID: 26725968.

Milind Javle, M.D.

of 24

129. Espinoza JA, Bizama C, García P, Ferreccio C, Javle M, Miquel JF, Koshiol J, Roa JC. The inflammatory inception of gallbladder cancer. Biochim Biophys Acta 1865(2):245-54, 4/2016. e-Pub 3/2016. PMID: 26980625.

130. Lee H, Wang K, Johnson A, Jones DM, Ali SM, Elvin JA, Yelensky R, Lipson D, Miller VA, Stephens PJ, Javle M, Ross JS. Comprehensive genomic profiling of extrahepatic cholangiocarcinoma reveals a long tail of therapeutic targets. J Clin Pathol 69(5):403-8, 5/2016. e-Pub 10/2015. PMID: 26500333.

131. Cloyd JM, Crane CH, Koay EJ, Das P, Krishnan S, Prakash L, Snyder RA, Varadhachary GR, Wolff RA, Javle M, Shroff RT, Fogelman D, Overman M, Wang H, Maitra A, Lee JE, Fleming JB, Katz MH. Impact of hypofractionated and standard fractionated chemoradiation before pancreatoduodenectomy for pancreatic ductal adenocarcinoma. Cancer. e-Pub 5/2016. PMID: 27243381.

132. Balaban EP, Mangu PB, Khorana AA, Shah MA, Mukherjee S, Crane CH, Javle MM, Eads JR, Allen P, Ko AH, Engebretson A, Herman JM, Strickler JH, Benson AB, Urba S, Yee NS. Locally Advanced, Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. e-Pub 5/2016. PMID: 27247216.

133. Zuo M, Rashid A, Wang Y, Jain A, Li D, Behari A, Kumar Kapoor V, Koay EJ, Chang P, Nicholas Vauthey J, Li Y, Espinoza JA, Carlos Roa J, Javle M. RNA sequencing-based analysis of gallbladder cancer reveals the importance of the liver X receptor and lipid metabolism in gallbladder cancer. Oncotarget. e-Pub 5/2016. PMCID: PMC5085230.

134. Ismael HN, Denbo J, Cox S, Crane CH, Das P, Krishnan S, Schroff RT, Javle M, Conrad C, Vauthey J, Aloia T. Biologic mesh spacer placement facilitates safe delivery of dose-intense radiation therapy: A novel treatment option for unresectable liver tumors. Eur J Surg Oncol. e-Pub 6/2016. PMID: 27296729.

135. Al-Shamsi HO, Anand D, Shroff RT, Jain A, Zuo M, Conrad C, Vauthey JN, Javle MM. BRCA-associated protein 1 mutant cholangiocarcinoma: an aggressive disease subtype. J Gastrointest Oncol 7(4):556-61, 8/2016. PMCID: PMC4963380.

136. Jain A, Javle M. Molecular profiling of biliary tract cancer: a target rich disease. J Gastrointest Oncol 7(5):797-803, 10/2016. PMCID: PMC5056250.

137. Chadha AS, Gunther JR, Minsky BD, Taniguchi CM, Mahmood U, Delclos ME, Suh Y, Sawakuchi GO, Park PC, Beddar S, Gupta S, Kaur H, Javle MM, Kaseb AO, Koay EJ, Das P, Crane CH, Krishnan S. Proton Therapy Outcomes for Localized, Unresectable Hepatocellular Carcinoma. Int J Radiat Oncol Biol Phys 96(2S):E181-E182, 10/2016. PMID: 27673993.

138. Amer AM, Tao R, Kang H, Chun Y, Vauthey JN, Javle MM, Kaseb AO, Crane CH, Koay EJ. Quantitative European Association for the Study of the Liver (qEASL) as an Early Biomarker of Response After Radiation Therapy for Intrahepatic Cholangiocarcinoma. Int J Radiat Oncol Biol Phys 96(2S):S202, 10/2016. PMID: 27675783.

139. Jain A, Kwong LN, Javle M. Genomic Profiling of Biliary Tract Cancers and Implications for Clinical Practice. Curr Treat Options Oncol 17(11):58, 11/2016. PMID: 27658789.

140. Abou-Alfa GK, Andersen JB, Chapman W, Choti M, Forbes SJ, Gores GJ, Hong TS, Harding JJ, Vander Heiden MG, Javle M, Kelley RK, Kwong LN, Lowery M, Merrell A, Miyabe K, Rhim A, Saha S, Sia D, Tanasanvimon S, Venook A, Valle JW, Walesky C, Whetstine J, Willenbring H, Zhu AX, Mayer D, Stanger BZ. Advances in cholangiocarcinoma research: report from the third Cholangiocarcinoma Foundation Annual Conference. J Gastrointest Oncol 7(6):819-827, 12/2016. PMCID: PMC5177567.

141. Javle M, Bekaii-Saab T, Jain A, Wang Y, Kelley RK, Wang K, Kang HC, Catenacci D, Ali S, Krishnan S, Ahn D, Bocobo AG, Zuo M, Kaseb A, Miller V, Stephens PJ, Meric-Bernstam F, Shroff R, Ross J. Biliary Cancer: Utility of Next Generation Sequencing for Clinical Management. Cancer 122(24):3838-3847, 12/2016. e-Pub 9/2016. PMID: 27622582.

142. Yamashita S, Loyer E, Chun YS, Javle M, Lee JE, Vauthey JN, Conrad C. Laparoscopic Management of Gallbladder Cancer: A Stepwise Approach. Ann Surg Oncol 23(Suppl 5):892-893, 12/2016. e-Pub 7/2016. PMID: 27456958.

143. Ahn DH, Javle M, Ahn CW, Jain A, Mikhail S, Noonan AM, Wu C, Shroff RT, Chen JL, Bekaii-Saab T. Next-generation sequencing survey of biliary tract cancer reveals the

Milind Javle, M.D.

of 24

association between tumor somatic variants and chemotherapy resistance. Cancer 122(23):3657-3666, 12/2016. e-Pub 8/2016. PMCID: PMC5222890.

144. Denbo JW, Bruno ML, Cloyd JM, Prakash L, Lee JE, Kim M, Crane CH, Koay EJ, Krishnan S, Das P, Minsky BD, Varadhachary G, Shroff R, Wolff R, Javle M, Overman MJ, Fogelman D, Aloia TA, Vauthey JN, Fleming JB, Katz MH. Preoperative Chemoradiation for Pancreatic Adenocarcinoma Does Not Increase 90-Day Postoperative Morbidity or Mortality. J Gastrointest Surg 20(12):1975-1985, 12/2016. e-Pub 10/2016. PMID: 27730398.

145. Chen J, Raju GS, Jogunoori W, Menon V, Majumdar A, Chen JS, Gi YJ, Jeong YS, Phan L, Belkin M, Gu S, Kundra S, Mistry NA, Zhang J, Su X, Li S, Lin SH, Javle M, McMurray JS, Rahlfs TF, Mishra B, White J, Rashid A, Beauchemin N, Weston BR, Shafi MA, Stroehlein JR, Davila M, Akbani R, Weinstein JN, Wu X, Mishra L. Mutational Profiles Reveal an Aberrant TGF-β-CEA Regulated Pathway in Colon Adenomas. PLoS One 11(4):e0153933, 2016. e-Pub 4/2016. PMCID: PMC4839765.

146. Chadha AS, Skinner HD, Gunther JR, Munsell MF, Das P, Minsky BD, Delclos ME, Chatterjee D, Wang H, Clemons M, George G, Singh PK, Katz MH, Fleming JB, Javle MM, Wolff RA, Varadhachary GR, Crane CH, Krishnan S. Phase I Trial of Consolidative Radiotherapy with Concurrent Bevacizumab, Erlotinib and Capecitabine for Unresectable Pancreatic Cancer. PLoS One 11(6):e0156910, 2016. e-Pub 6/2016. PMID: 27336466.

147. Cloyd JM, Katz MH, Prakash L, Varadhachary GR, Wolff RA, Shroff RT, Javle M, Fogelman D, Overman M, Crane CH, Koay EJ, Das P, Krishnan S, Minsky BD, Lee JH, Bhutani MS, Weston B, Ross W, Bhosale P, Tamm EP, Wang H, Maitra A, Kim MP, Aloia TA, Vauthey JN, Fleming JB, Abbruzzese JL, Pisters PW, Evans DB, Lee JE. Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience. J Gastrointest Surg 21(1):164-174, 1/2017. e-Pub 10/2016. PMID: 27778257.

148. Bendell JC, Javle M, Bekaii-Saab TS, Finn RS, Wainberg ZA, Laheru DA, Weekes CD, Tan BR, Khan GN, Zalupski MM, Infante JR, Jones S, Papadopoulos KP, Tolcher AW, Chavira RE, Christy-Bittel JL, Barrett E, Patnaik A. A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor. Br J Cancer 116(5):575-583, 2/2017. e-Pub 2/2017. PMCID: PMC5344293.

149. Chadha AS, Liu G, Chen HC, Das P, Minsky BD, Mahmood U, Delclos ME, Suh Y, Sawakuchi GO, Beddar S, Katz MH, Fleming JB, Javle MM, Varadhachary GR, Wolff RA, Crane CH, Wang X, Thames H, Krishnan S. Does Unintentional Splenic Radiation Predict Outcomes After Pancreatic Cancer Radiation Therapy? Int J Radiat Oncol Biol Phys 97(2):323-332, 2/2017. e-Pub 11/2016. PMID: 28068240.

150. Yamashita S, Passot G, Aloia TA, Chun YS, Javle M, Lee JE, Vauthey JN, Conrad C. Prognostic value of carbohydrate antigen 19-9 in patients undergoing resection of biliary tract cancer. Br J Surg 104(3):267-277, 2/2017. e-Pub 1/2017. PMID: 28052308.

151. Golan T, Sella T, O'Reilly EM, Katz MH, Epelbaum R, Kelsen DP, Borgida A, Maynard H, Kindler H, Friedmen E, Javle M, Gallinger S. Overall survival and clinical characteristics of BRCA mutation carriers with stage I/II pancreatic cancer. Br J Cancer 116(6):697-702, 3/2017. e-Pub 2/2017. PMCID: PMC5355924.

152. Yamashita S, Koay EJ, Passot G, Shroff R, Raghav KP, Conrad C, Chun YS, Aloia TA, Tao R, Kaseb A, Javle M, Crane CH, Vauthey JN. Local therapy reduces the risk of liver failure and improves survival in patients with intrahepatic cholangiocarcinoma: A comprehensive analysis of 362 consecutive patients. Cancer 123(8):1354-1362, 4/2017. e-Pub 12/2016. PMCID: PMC5384875.

153. Koay EJ, Odisio BC, Javle M, Vauthey JN, Crane CH. Management of unresectable intrahepatic cholangiocarcinoma: how do we decide among the various liver-directed treatments? Hepatobiliary Surg Nutr 6(2):105-116, 4/2017. PMCID: PMC5411273.

154. Gulhati P, Raghav K, Shroff RT, Varadhachary GR, Kopetz S, Javle M, Qiao W, Wang H, Morris J, Wolff RA, Overman MJ. Bevacizumab combined with capecitabine and oxaliplatin in patients with advanced adenocarcinoma of the small bowel or ampulla of vater: A single-center, open-label, phase 2 study. Cancer 123(6):1011-1017, 5/2017. e-Pub 11/2016. PMCID: PMC5548379.

Milind Javle, M.D.

of 24

155. Lapin M, Tjensvoll K, Oltedal S, Javle M, Smaaland R, Gilje B, Nordgård O. Single-cell mRNA profiling reveals transcriptional heterogeneity among pancreatic circulating tumour cells. BMC Cancer 17(1):390, 5/2017. e-Pub 5/2017. PMCID: PMC5452374.

156. Cloyd JM, Wang H, Overman M, Zhao J, Denbo J, Prakash L, Kim MP, Shroff R, Javle M, Varadhachary GR, Fogelman D, Wolff RA, Koay EJ, Das P, Maitra A, Aloia TA, Vauthey JN, Fleming JB, Lee JE, Katz MHG. Influence of Preoperative Therapy on Short- and Long-Term Outcomes of Patients with Adenocarcinoma of the Ampulla of Vater. Ann Surg Oncol 24(7):2031-2039, 7/2017. e-Pub 1/2017. PMID: 28124275.

157. Golan T, Raitses-Gurevich M, Kelley RK, Bocobo AG, Borgida A, Shroff RT, Holter S, Gallinger S, Ahn DH, Aderka D, Apurva J, Bekaii-Saab T, Friedman E, Javle M. Overall Survival and Clinical Characteristics of BRCA-Associated Cholangiocarcinoma: A Multicenter Retrospective Study. Oncologist 22(7):804-810, 7/2017. e-Pub 5/2017. PMCID: PMC5507643.

158. Golan T, Javle M. DNA Repair Dysfunction in Pancreatic Cancer: A Clinically Relevant Subtype for Drug Development. J Natl Compr Canc Netw 15(8):1063-1069, 8/2017. PMID: 28784866.

159. Janku F, Zhang S, Waters J, Liu L, Huang HJ, Subbiah V, Hong DS, Karp DD, Fu S, Cai X, Ramzanali NM, Madwani K, Cabrilo G, Andrews DL, Zhao Y, Javle M, Kopetz ES, Luthra R, Kim HJ, Gnerre S, Satya RV, Chuang HY, Kruglyak KM, Toung J, Zhao C, Shen R, Heymach JV, Meric-Bernstam F, Mills GB, Fan JB, Salathia NS. Development and Validation of an Ultradeep Next-Generation Sequencing Assay for Testing of Plasma Cell-Free DNA from Patients with Advanced Cancer. Clin Cancer Res 23(18):5648-5656, 9/2017. e-Pub 5/2017. PMCID: PMC5600825.

160. Goldstein JB, Tang C, Hess KR, Hong D, Subbiah V, Janku F, Fu S, Karp DD, Naing A, Tsimberidou AM, Wheler J, Zinner R, Javle M, Varadhachary GR, Wolff RA, Fogelman DR, Meric-Bernstam F, Piha-Paul SA. Outcomes of phase I clinical trials for patients with advanced pancreatic cancer: update of the MD Anderson Cancer Center experience. Oncotarget 8(50):87163-87173, 10/2017. e-Pub 8/2017. PMCID: PMC5675623.

161. Cloyd JM, Wang H, Egger ME, Tzeng CD, Prakash LR, Maitra A, Varadhachary GR, Shroff R, Javle M, Fogelman D, Wolff RA, Overman MJ, Koay EJ, Das P, Herman JM, Kim MP, Vauthey JN, Aloia TA, Fleming JB, Lee JE, Katz MHG. Association of Clinical Factors With a Major Pathologic Response Following Preoperative Therapy for Pancreatic Ductal Adenocarcinoma. JAMA Surg 152(11):1048-1056, 11/2017. e-Pub 7/2017. PMCID: PMC5710421.

162. Hassan MM, Botrus G, Abdel-Wahab R, Wolff RA, Li D, Tweardy D, Phan AT, Hawk E, Javle M, Lee JS, Torres HA, Rashid A, Lenzi R, Hassabo HM, Abaza Y, Shalaby AS, Lacin S, Morris J, Patt YZ, Amos CI, Khaderi SA, Goss JA, Jalal PK, Kaseb AO. Estrogen Replacement Reduces Risk and Increases Survival Times of Women With Hepatocellular Carcinoma. Clin Gastroenterol Hepatol 15(11):1791-1799, 11/2017. e-Pub 6/2017. PMCID: PMC5901750.

163. Sakellariou-Thompson D, Forget MA, Creasy C, Bernard V, Zhao L, Kim YU, Hurd MW, Uraoka N, Parra ER, Kang Y, Bristow CA, Rodriguez-Canales J, Fleming JB, Varadhachary G, Javle M, Overman MJ, Alvarez HA, Heffernan TP, Zhang J, Hwu P, Maitra A, Haymaker C, Bernatchez C. 4-1BB Agonist Focuses CD8(+) Tumor-Infiltrating T-Cell Growth into a Distinct Repertoire Capable of Tumor Recognition in Pancreatic Cancer. Clin Cancer Res 23(23):7263-7275, 12/2017. e-Pub 9/2017. PMCID: PMC6097625.

164. Javle M, Lowery M, Shroff RT, Weiss KH, Springfeld C, Borad MJ, Ramanathan RK, Goyal L, Sadeghi S, Macarulla T, El-Khoueiry A, Kelley RK, Borbath I, Choo SP, Oh DY, Philip PA, Chen LT, Reungwetwattana T, Van Cutsem E, Yeh KH, Ciombor K, Finn RS, Patel A, Sen S, Porter D, Isaacs R, Zhu AX, Abou-Alfa GK, Bekaii-Saab T. Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma. J Clin Oncol 36(3):JCO2017755009, 1/2018. e-Pub 11/2017. PMCID: PMC6075847.

165. Castillo J, Bernard V, San Lucas FA, Allenson K, Capello M, Kim DU, Gascoyne P, Mulu FC, Stephens BM, Huang J, Wang H, Momin AA, Jacamo RO, Katz M, Wolff R, Javle M, Varadhachary G, Wistuba II, Hanash S, Maitra A, Alvarez H. Surfaceome profiling enables

Milind Javle, M.D.

of 24

isolation of cancer-specific exosomal cargo in liquid biopsies from pancreatic cancer patients. Ann Oncol 29(1):223-229, 1/2018. e-Pub 9/2017. PMCID: PMC6248757.

166. Gulhati P, Raghav K, Shroff R, Varadhachary G, Javle M, Qiao W, Wang H, Morris J, Wolff R, Overman MJ. Phase II Study of Panitumumab in RAS Wild-Type Metastatic Adenocarcinoma of Small Bowel or Ampulla of Vater. Oncologist 23(3):277-e26, 3/2018. e-Pub 12/2017. PMCID: PMC5905687.

167. Wang YN, Lee HH, Chou CK, Yang WH, Wei Y, Chen CT, Yao J, Hsu JL, Zhu C, Ying H, Ye Y, Wang WJ, Lim SO, Xia W, Ko HW, Liu X, Liu CG, Wu X, Wang H, Li D, Prakash LR, Katz MH, Kang Y, Kim M, Fleming JB, Fogelman D, Javle M, Maitra A, Hung MC. Angiogenin/Ribonuclease 5 Is an EGFR Ligand and a Serum Biomarker for Erlotinib Sensitivity in Pancreatic Cancer. Cancer Cell 33(4):752-769.e8, 4/2018. e-Pub 3/2018. PMCID: PMC5893359.

168. Lunsford KE, Javle M, Heyne K, Shroff RT, Abdel-Wahab R, Gupta N, Mobley CM, Saharia A, Victor DW, Nguyen DT, Graviss EA, Kaseb AO, McFadden RS, Aloia TA, Conrad C, Li XC, Monsour HP, Gaber AO, Vauthey JN, Ghobrial RM, Methodist–MD Anderson Joint Cholangiocarcinoma Collaborative Committee (MMAJCCC). Liver transplantation for locally advanced intrahepatic cholangiocarcinoma treated with neoadjuvant therapy: a prospective case-series. Lancet Gastroenterol Hepatol 3(5):337-348, 5/2018. e-Pub 3/2018. PMID: 29548617.

169. Abdel-Wahab R, Varadhachary GR, Bhosale PR, Wang X, Fogelman DR, Shroff RT, Overman MJ, Wolff RA, Javle M. Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma. J Hematol Oncol 11(1):71, 5/2018. e-Pub 5/2018. PMCID: PMC5975422.

170. Sheth RA, Sabir SH, Parmet P, Amin R, Kuban JD, Huang SY, Mahvash A, Fogelman D, Javle M, Wallace MJ. Portomesenteric Venous Stenting for Palliation of Ascites and Variceal Bleeding Caused by Prehepatic Portal Hypertension. Oncologist 23(6):712-718, 6/2018. e-Pub 12/2017. PMCID: PMC6067944.

171. Groisberg R, Hong DS, Roszik J, Janku F, Tsimberidou AM, Javle M, Meric-Bernstam F, Subbiah V. Clinical Next-Generation Sequencing for Precision Oncology in Rare Cancers. Mol Cancer Ther 17(7):1595-1601, 7/2018. e-Pub 4/2018. PMCID: PMC6310221.

172. Parseghian CM, Patnana M, Bhosale P, Hess KR, Shih YT, Kim B, Kopetz S, Overman MJ, Varadhachary GR, Javle M, Naing A, Piha-Paul S, Hong D, Le H, Subbiah V, Pant S. Evaluating for Pseudoprogression in Colorectal and Pancreatic Tumors Treated With Immunotherapy. J Immunother 41(6):284-291, Jul/Aug, 7/2018. PMCID: PMC6028046.

173. Lunsford KE, Javle M, Gaber AO, Vauthey JN, Ghobrial RM. Liver transplantation for locally advanced intrahepatic cholangiocarcinoma - Authors' reply. Lancet Gastroenterol Hepatol 3(8):529-530, 8/2018. PMID: 30047444.

174. Fountzilas C, Javle M, Tan W, Ma Y, Fetterly G, Iyer R, Johnson C. A phase 1, open-label, dose escalation study of intravenous paricalcitol in combination with gemcitabine in patients with advanced malignancies. Cancer 124(19):3890-3899, 10/2018. e-Pub 10/2018. PMID: 30299542.

175. Elganainy D, Holliday EB, Taniguchi CM, Smith GL, Shroff R, Javle M, Raghav K, Kaseb A, Aloia TA, Vauthey JN, Tzeng CD, Herman JM, Koong AC, Krishnan SX, Minsky BD, Crane CH, Das P, Koay EJ. Dose escalation of radiotherapy in unresectable extrahepatic cholangiocarcinoma. Cancer Med 7(10):4880-4892, 10/2018. e-Pub 8/2018. PMCID: PMC6198206.

176. Gulhati P, Prakash L, Katz MHG, Wang X, Javle M, Shroff R, Fogelman D, Lee JE, Tzeng CD, Lee JH, Weston B, Tamm E, Bhosale P, Koay EJ, Maitra A, Wang H, Wolff RA, Varadhachary GR. First-Line Gemcitabine and Nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma. Ann Surg Oncol. e-Pub 10/2018. PMID: 30324485.

177. Mehrotra R, Tulsyan S, Hussain S, Mittal B, Singh Saluja S, Singh S, Tanwar P, Khan A, Javle M, Hassan MM, Pant S, De Aretxabala X, Sirohi B, Rajaraman P, Kaur T, Rath GK. Genetic landscape of gallbladder cancer: Global overview. Mutat Res 778:61-71, Oct - Dec, 10/2018. e-Pub 8/2018. PMID: 30454684.

Milind Javle, M.D.

of 24

178. Lapin M, Oltedal S, Tjensvoll K, Buhl T, Smaaland R, Garresori H, Javle M, Glenjen NI, Abelseth BK, Gilje B, Nordgård O. Fragment size and level of cell-free DNA provide prognostic information in patients with advanced pancreatic cancer. J Transl Med 16(1):300, 11/2018. e-Pub 11/2018. PMCID: PMC6218961.

179. Bhatty M, Kato S, Piha-Paul SA, Naing A, Subbiah V, Huang HJ, Karp DD, Tsimberidou AM, Zinner RG, Hwu WJ, Javle M, Patel SP, Hu MI, Varadhachary GR, Conley AP, Ramzanali NM, Holley VR, Kurzrock R, Meric-Bernstam F, Kwang Chae Y, Kim KB, Falchook GS, Janku F. Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients With BRAF-mutated melanoma and other advanced malignancies. Cancer. e-Pub 11/2018. PMID: 30383888.

180. Koay EJ, Lee Y, Cristini V, Lowengrub JS, Kang Y, Lucas FAS, Hobbs BP, Ye R, Elganainy D, Almahariq M, Amer AM, Chatterjee D, Yan H, Park PC, Rios Perez MV, Li D, Garg N, Reiss KA, Yu S, Chauhan A, Zaid M, Nikzad N, Wolff RA, Javle M, Varadhachary GR, Shroff RT, Das P, Lee JE, Ferrari M, Maitra A, Taniguchi CM, Kim MP, Crane CH, Katz MH, Wang H, Bhosale P, Tamm EP, Fleming JB. A Visually Apparent and Quantifiable CT Imaging Feature Identifies Biophysical Subtypes of Pancreatic Ductal Adenocarcinoma. Clin Cancer Res 24(23):5883-5894, 12/2018. e-Pub 8/2018. PMCID: PMC6279613.

181. Finn RS, Ahn DH, Javle MM, Tan BR, Weekes CD, Bendell JC, Patnaik A, Khan GN, Laheru D, Chavira R, Christy-Bittel J, Barrett E, Sawyer MB, Bekaii-Saab TS. Phase 1b investigation of the MEK inhibitor binimetinib in patients with advanced or metastatic biliary tract cancer. Invest New Drugs 36(6):1037-1043, 12/2018. e-Pub 5/2018. PMID: 29785570.

182. Bernard V, Kim DU, San Lucas FA, Castillo J, Allenson K, Mulu FC, Stephens BM, Huang J, Semaan A, Guerrero PA, Kamyabi N, Zhao J, Hurd MW, Koay EJ, Taniguchi CM, Herman JM, Javle M, Wolff R, Katz M, Varadhachary G, Maitra A, Alvarez HA. Circulating Nucleic Acids Associate with Outcomes of Patients with Pancreatic Cancer. Gastroenterology 156(1):108-118.e4, 1/2019. e-Pub 9/2018. PMID: 30240661.

183. Odisio BC, Krampitz GW, Murthy R, Mahvash A, Javle M, Vauthey JN. Preoperative drainage for perihilar cholangiocarcinoma. Lancet Gastroenterol Hepatol 4(1):10-11, 1/2019. e-Pub 12/2018. PMID: 30527574.

Invited Articles 1. Javle M. Gastroparesis from Advanced Cancer. Uptodate online, 2008.

Editorials N/A

Other Articles 1. Jain A, Javle M. Personalized therapy for biliary tract cancer. Current Opinion in Oncology. In

Press.

Abstracts 1. Stephens P, Wang K, Palma NA, Chmielecki J, Shroff RT, Churl C, Frampton GM, ALi SM,

Javle MM, Ross JS. Comprehensive genomic profiling of gallbladder adenocarcinoma and frequent genomic-derived targets of therapy. J Clin Oncol 32(15):4142, 2014.

2. Anand D, Churi C, Rashid A, Shroff RT, Zuo MX, Conrad C, Vauthey JN, Javle MM. BAP1 mutation-associated cholangiocarcinoma: An aggressive disease. J Clin Oncol 33(3):420, 1/2015.

3. Rogers JE, Nguyen V, Nogueras-Gonzalez GM, Crane Ch, Das P, Krishnan S, Law L, Javle MM, Kaseb AO, Shroff RT. Charterization of unresectable cholangiocardinoma patients treated with or without chemoradiation. J Clin Oncol 33(3):403, 1/2015.

4. Ross JS, Wang K, Catenacci DVT, Chmielecki J, Ali AM, Elvin JA, Yelensky R, Lipson D, Hawryluk MJ, Miller VA, Stephens PJ, Javle MM. Comprehensive genomic profiling of biliary tract cancers tumor-specific differences and genomic alterations. ASCO Meeting Abstracts 33(3_suppl):231, 1/2015.

5. Goldstein JB, Tang C, Hong DS, Subbiah V, Janku F, Hess KR, Fu SQ, Karp DD, Naing A, Tsimberidou AM, Wheler JJ, Zinner R, Javle MM, Varadhachary GR, Wolff RA, Fogelman DR, Meric-Bernstam F, Piha-Paul SA. Evolution of phase 1 trials for patients with advanced

Milind Javle, M.D.

of 24

pancreatic cancer: An update on the experience from MD Anderson Cancer Center. J Clin Oncol 33(3):320, 1/2015.

6. Golan T, Sella T, Javle MM, Borgida A, O'Reilly EM, Kelsen DP, Epelbaum R, Kindler HL, Katz MHG, Gallinger S. Overall survival and clinical characteristics in BRCA mutation carriers with stage I/II pancreatic cancer (PC). J Clin Oncol 33(3):287, 1/2015.

7. Crane CH, Chanda AS, Koay EJ, Varadhachary GR, Das P, Javle MM, Suh Y, Wolff RA, Fleming JB, Katz MHG, Fogelman DR, Shroff RT, Lee JE, Krishnan S. Effect of dose-escalation of IMRT for unresectable pancreatic cancer 1 cm away from the luminal mucosa on long-term survival. J Clin Oncol 33(3):354, 2/2015.

8. Goldstein JB, NOgueras-Gonzalez GM, Javle MM, Katz MHG, Varadhachary GR, Fogelman DR, Overman MJ, Wolff RA, Shroff RT. A retrospective single institution review of 90 pancreatic adenosquamous cancer (PASC) patients (pts). J Clin Oncol 33(15):4125, 5/2015.

9. Ross JS, Wang K, Javle MM, Catenacci DVT, Shroff RT, Ali SM, Elvin JA, Chmielecki J, Yelensky R, Lipson D, Miller VA, Stepens PJ, Meric-Bernstam F. Comprehensive genomic profiling of biliary tract cancers to reveal tumor-specific differences and frequency of clinically relevant genomic alterations. J Clin Oncol 33(15):4009, 5/2015.

10. Al-Shamsi HO, Barrera CD, Surapaneni R, Kang H, Shroff RT, Janku F, Krishnan S, Zuo MX, Wolff RA, Kaseb AO, Thomas MB, Siegel AB, Javle MM. HER2/neu-directed therapy for biliary tract cancer. J Clin Oncol 33(15):e15137, 5/2015.

11. Hong TS, Wo JYL, Yeap BY, Ben-Josef E, McDonnell EI, Drapek LC, Blaszhkowsky LS, Kwak EL, Clark JW, Goyal L, Ryan DP, Javle MM, Wolfgang JA, Arellano R, Mullen JT, Ferrone C, Tanabe K, DeLaney TF, Crane CH, Shu AX. Multi-institutional phase II study of high dose, hypofractionated proton beam therapy (HF-PBT) for unresectable primary liver cancers: Long term outcomes in patients (pts) with intrahepatic cholangiocarcinoma (ICC). J Clin Oncol 33(15):4020, 5/2015.

12. Varadhachary GR, Fleming JB, Crane, Ch, Fogelman DR, Shroff RT, Lee JE, Lee JH, Tamm EP, Bhosale P, Das P, Krishman S, Javle MM, Weston B, Wang HM, Wolff RA, Katz MGH. Phase II study of preoperation mFOLFIRNOX and chemoradiation for high-risk resectable and borderline resectable pancreatic adenocarcinoma. J Clin Oncol 33(3):362, 2015.

13. Hong TS, Wo JYL, Ben-Josef E, McDonnell E, Drapek LC, Blaszkowsky LS, Kwak EL, Clark JW, Goyal L, Ryan DP, Javle MM, Arellano R, Wolfgang JA, Mullen JT, Ferrone C, Tanabe K, DeLaney TF, Crane CH, Zhu AX. A multi-institutional phase II study of high-dose hypofractionated proton beam therapy (HF-PBT) for unresectable primary liver cancers: Long-term outcomes in patients (pts) with hepatocellular carcinoma (HCC). J Clin Oncol 34(4):376, 2/2016.

14. Javle MM, Shroff RT, Zhu A, Sadeghi S, Choo S, Borad MJ, Lowery MA, El-Khoueiry A, Macurulla T, Philip PA, Oh DY, Van Cutsem E, Yeh KH, Isaacs R, McGarry C, Sen S, Bekaii-Saab TS. A phase 2 study of BGJ398 in patients (pts) with advanced or metastiatic FGFR-altered cholangiocarcinoma (CCA) who failed or are intolerant to platinum-based chemotherapy. J Clin Oncol 34(4):335, 2/2016.

15. Crane CH, Tao R, Bhosale P, Javle MM, Shroff RT, Aloia TA, Kaseb AO, Koay EJ, Bishop AJ, Swanick CW, Hong TS, Das P, Krishnan S. Effect of ablative radiotherapy on survival in patients with inoperable intrahepatic cholangiocarcinoma: A dose response analysis. J Clin Oncol 34(4):294, 2/2016.

16. Javle MM, Rashid A, Kar SP, Schalper K, Wang N, Peto M, Vauthey JN, Aloia TA, De Aretxabala X, Mills GB, Spellman P, Roa I. Identification of unique somatic mutations with functional relevance through genetic characterization of gallbladder cancer (GB ca). J Clin Oncol 31(4):214, 2/2016.

17. Ahn DH, Ahn C, Jain A, Mikhail S, Wu CSY, Goldberg RM, Ciombor KK, Noonan AM, Sadavartia P, Shroff RT, Javle MM, Chen JL, Bekaii-Saab TS. Next Generation Sequencing (NGS) to reveal mutations in IDH1 and its effect on patient (pt) outcomes in advanced biliary tract cancer (aBTC) who received gemcitabine and cisplatin (GC). J Clin Oncol 34(4):287, 2/2016.

18. Golan T, Raitses-Gurevich M, Kelley RK, Bocobo AG, Borgida A, Shroff RT, Holter S, Gallinger S, Lowery MA, Abou-Alfa GK, Ahn DH, Jain A, Bekaii-Saab TS, Friedman E, Javle

Milind Javle, M.D.

of 24

MM. Overall survival and clinical characteristics of BRCA germline/somatic cholangiocarcinoma (CCA). J Clin Oncol 34(4):244, 2/2016.

19. Gulhati P, Raghave KPS, Shroff RT, Varadhachary GR, Kopetz S, Javle MM, Qiao W, Wang HM, Morris J, Wolff RA, Overman MJ. Phase II study of bevacizumab combined with capecitabine and oxaliplatin in patients with advanced adenocarcinoma of the small bowel or ampulla of vater. J Clin Oncol 34(4):144, 2/2016.

20. Wang XS, Shi Q, Dougherty PM, Eng C, Mendoza TR, Williams LA, Fogelman DR, Cleeland CS. Prechemotherapy Touch Sensation Deficits Predict Oxaliplatin-Induced Neuropathy in Patients with Colorectal Cancer. Oncology 90(3):127-35, 2/2016. PMCID: PMCPMC4794365.

21. Infante JR, Naing A, Papadopoulos KP, Autio KA, Ott PA, Wong DJL, Falchook GS, Patel MR, Pant S, Whiteside M, Bendell JC, Bauer TM, Janku F, Javle MM, Hong DS, Oft M. A first-in-human dose escalation study of PEGylated recombinant human IL-10 (AM0010) in advanced solid tumors. J Clin Oncol 33(15):3017, 5/2016.

22. Overman MJ, Lopez CD, Benson AB, Neelapu SS, Mettu NB, Ko AH, Chung VM, Nemunaitis JJ, Reeves JA, Bendell JC, Philip PA, Dalal R, Fardis M, Greer J, Wang X, Inamdar S, Lannutti BJ, Rothbaum W, Izumi R, Javle MM. A randomized phase 2 study of the Bruton tyrosine kinase (Btk) inhibitor acalabrutinib alone or with pembrolizumab for metastiatic pancreatic cancer (mPC). ASCO Meeting Abstracts 34(15_suppl):4130, 5/2016.

23. Jain A, Schroff RT, Kelley RK, Kaseb AO, Wang Y, Abdel-Wahab R, Ahn DH, Bocobo AG, Meric-Bernstam F, Isaacs R, Bekaii-Saab TS, Javle MM. FGFR pathway genetic aberrations in cholangiocarcinoma: Demographics and experience with targeted therapy. ASCO Meeting Abstracts 34(15_suppl):109, 5/2016.

24. Ahn DH, Javle MM, Ahn C, Jain A, Mikhail S, Shroff RT, Ciombor KK, Noonan AM, Wu CS, Chen JL, Bakaii-Saab TS. Next-generation sequencing (NGS) survey of biliary tract cancer (BTC) to reveal the association between tumor somatic variants and chemotherapy resistance. ASCO Meeting Abstracts 34(15_suppl):4079, 5/2016.

25. Murthy R, Rachakonda V, Mahvash A, Huang SY, Sabir SH, Subbiah V, Janku F, Kaseb AO, Javle MM, Murthy A. Percutaneous transhepatic biliary drainage in hepatopancreaticobiliary cancer: Contemporary efficacy. ASCO Meeting Abstracts 34(15_suppl):e21637, 5/2016.

26. Kato S, Janku F, Piha-Paul SA, Naing A, Karp DD, Tsimberidou AM, Subbiah V, Zinner R, Hwu W, Javle MM, Parkhurst KL, Ramzanali NM, Kurzrock R, Meric-Bernstam F, Chae YK, Kim K, Falchook GS. Phase 1 study of combination vemurafenib, carboplatin, and paclitaxel in patients (pts) with BRAF-mutant advanced cancer. ASCO Meeting Abstracts 33(15_suppl):105, 5/2016.

27. Shalaby AS, Botrus G, Kaseb AO, Li D, Abdel-Wahab R, Wolff RA, Javle MM, Hawk E, Hassan M. The protective effect of physical activity on risk of hepatocellular carcinoma in USA. ASCO Meeting Abstracts 34(15_suppl):e15642, May 31, 2016, 2016.

Book Chapters 1. M Javle, D Raghavan. Total androgen blockage for prostate cancer: the end does not justify

the means. In: Genitourinary Tract Malignancies. Ed(s) Pienta K (ed.). Kluwer Academic Publishers: Boston, Dordrecht, London, pp 201-210, 1996.

2. M Javle, G Varma. Chemotherapy for palliation of pain: “about quality, not quantity". In: Cancer Pain: Pharmacologic, Interventional, and Palliative Care. Ed(s) Oscar de Leon-Cassola (ed), 2006.

3. MM Javle, M Fisch. Overview of palliative management of pancreatic cancer. In: Handbook of Pancreatic Cancer, 2009.

4. R Shroff, M Javle, RA Wolff. Pancreatic Cancer. In: MD Anderson Cancer Handbook, 2010. 5. MM Javle. Personalized therapy for pancreatic cancer. In: Principles of Molecular

Diagnostics and Personalized Cancer Medicine. Ed(s) D Tan, H Lynch, 2012. 6. M Javle. Hepatobiliary Cancer. In: MD Anderson Manual of Medical Oncology, 2014. 7. M Javle. Pancreatic Cancer. In: MD Anderson Manual of Medical Oncology, 2014.

Books (edited and written) N/A

Letters to the Editor N/A

Milind Javle, M.D.

of 24

Manuals, Teaching Aids, Other Teaching Publications N/A

Other Publications N/A

EDITORIAL AND REVIEW ACTIVITIES Editor/Service on Editorial Board(s)

N/A Member of Editorial Review Board

Member of Editorial Board, Journal of Gastrointestinal Oncology, BMC Gastroenterology, 2008-present Member, Journal of Hematology and Oncology, 2009-present Editorial Member, Journal of Gastrointestinal Oncology, 2010-present IRG Reviewer, Cholangiocarcinoma, The University of Texas MD Anderson Cancer Center, 2013-present

Journal Reviewer Reviewer, Cancer Chemotherapy and Pharmacology, Oncology, American Journal of Clinical Oncology, Diseases of Esophagus, Cancer Investigation, Lancet Oncology, 2008-present Reviewer, Journal of Clinical Oncology, Clinical Cancer Research, Cancer Investigation, 2008-present Reviewer, Lastgarten Foundation, 2012-present

Other Editorial and Review Activities N/A

TEACHING Teaching Within Current Institution -

Formal Teaching Courses Taught

N/A

Training Programs N/A

Other Formal Teaching Lecturer, "Pancreatic Cancer: Challenging the Status Quo" The Division of Cancer Medicine and Internal Medicine Combined Grand Rounds

2/2012 Supervisory Teaching

Committees Advisory Committees

N/A Supervisory Committees

N/A Examining Committees

N/A Direct Supervision

Undergraduate and Allied Health Students N/A

Medical Students N/A

Graduate Students

Milind Javle, M.D.

of 24

N/A Postdoctoral Research Fellows

N/A Clinical Residents and Fellows

Research mentor, Cancer Medicine, Davide Melisi, 1/2007-present Research mentor, Cancer Medicine, Rachna Shroff, 1/2008-present Research mentor, Drs. Jane Huang and Nishin Bhadkamkar, 1/2009-present

Other Supervisory Teaching N/A

Teaching Outside Current Institution Formal Teaching

Courses Taught N/A

Training Programs N/A

Other Formal Teaching N/A

Supervisory Teaching Committees

Advisory Committees N/A

Supervisory Committees N/A

Examining Committees N/A

Direct Supervision Undergraduate and Allied Health Students

N/A Medical Students

N/A Graduate Students

N/A Postdoctoral Research Fellows

N/A Clinical Residents and Fellows

N/A Other Supervisory Teaching

N/A

CONFERENCES AND SYMPOSIA Organization of Conferences/Symposia (Include chairing session)

ASCO 2008 Annual Meeting, ASCO Annual Meeting, Session co-chair for poster discussion of Upper GI abstracts, 2008 ASCO 2009 annual meeting, ASCO Annual Meeting, Session chair for oral presentation of Upper GI abstracts, 2009 ASCO Scientific Program Committee Meeting, Washington, DC, Board Member, 3/2010 ASCO 2013 Annual Meeting, ASCO Annual Meeting, Chair, 2013

Milind Javle, M.D.

of 24

ASCO 2014 Annual Meeting, ASCO Annual Meeting, Chair, 2014 ASCO 2016 Annual Meeting, Chicago, IL, role, 2016

Presentations at National or International Conferences Invited

Neoadjuvant Chemotherapy is warranted for locally advanced esophageal cancer, Surgical Conference Debate, Roswell Park Cancer Institute, 2/5/2002 Gastrointestinal stromal tumors, Grand rounds, Veterans Hospital, Buffalo, NY, 10/22/2002 Colon cancer - Update for the internist, Medical Grand Rounds, Buffalo General Hospital, Buffalo, NY, 2/6/2003 Pancreatic Cancer, Medical Grand Rounds, Millard Fillmore Hospital, Buffalo, NY, 3/17/2003 ASCO Update, Roswell Park Cancer Institute, Buffalo, NY, 6/14/2003 Surgical resection in multimodality management of localized esophageal cancer improves outcome: a thirty year experience, Gastrointestinal Cancer Symposium Current Status and Future Directions for Prevention and Management, San Francisco, CA, 1/22/2004 Colorectal Cancer, Core Lecture to Fellows, Veterans Administration Hospital, Buffalo, NY, 2/19/2004 Cox-2 Inhibition and Cancer, Surgical Grand Rounds, Roswell Park Cancer Institute, Buffalo, NY, 4/7/2004 Colorectal cancer: Reason for Optimism. Lessons from the past, hopes for the future, Annual Spring Clinical Symposium, Wyoming County Community Hospital, WY, 4/21/2004 Pancreatic Cancer: Lessons from the Past, Hope for the Future. Educational Session, Epidemiology of Pancreatic Cancer, Roswell Park Cancer Institute, Buffalo, NY, 6/12/2004 Significant Effect of Single Nucleotide Polymorphisms of Gemcitabine Metabolic Genes on Pancreatic Cancer Survival and Drug Toxicity, 2008 Gastrointestinal Cancers Symposium Science and Multidisciplinary Management of GI Malignancies, ASCO - GI Cancer Symposium, Orlando, FL, 1/25/2008 RAC Committee Review Meeting, NIH, Bethesda, MD, 6/17/2008 Significant Effect of Single Nucleotide Polymorphisms of Gemcitabine Metabolic Genes on Pancreatic Cancer Survival and Drug Toxicity, ESMO International Symposium 10th World Congress on Gastrointestinal Cancer, Barcelona, Spain, 6/25/2008 Bristol-Myers Squibb Pancreatic Advisory Board, Miami, FL, 12/5/2008 ASCO Scientific Program - Committee Meeting, Orlando, FL, 2/13/2009 Gallbladder Cancer, Chile Gallbladder Cancer Workshop, Santiago, Chile, 11/28/2009 Management of Gallbladder Cancer, GI Medical Oncology Fellows Training Program, Mumbai, India, 12/29/2009 Pancreatic Cancer, XXVIII National Congress of Oncology, Cancun, Mexico, 10/29/2010 Pancreatic Cancer: Poster Child for Personalized Therapy, Grand Rounds at Roswell Park Cancer Institute, Buffalo, NY, 12/10/2010 Newer Drugs - Hope for the future, International Association Pancreatology, Cochin, Maradu, India, 2/13/2011 Recent advances in multimodality therapy for hepatopancreatobiliary malignancy, Americas Hepato-Pancreato-Biliary Association - Gallbladder Cancer Adjuvant Therapy, Santiago, Chile, 6/28/2011 GI Malignancies, Portland, OR, 4/20/2012 Gallbladder Cancer, Global Academic Program, Oslo, Norway, 5/13/2012

Milind Javle, M.D.

of 24

Global Academic Program Meeting - India, New Delhi, India, 2/28/2013 ASCO Scientific Program, ASCO, Alexandria, VA, 3/15/2013 Management Of Gastric, Pancreatic And Hepatic Cancer, Puerto Rico Cancer Conference Series 2013, San Juan, PR, 8/17/2013 Milind Javle, MD. Biliary Tract Cancer - Review and Case Presentations, Mundipharma-EDO, Mundipharma, Seville, Spain, 10/11/2018 Milind Javle, MD. Perspective on systemic therapies and molecular profiling for biliary tract cancers, Prime Oncology, West Oncology Conference at Graceland, Memphis, TN, 11/10/2018

Other, Including Scientific Exhibitions Colorectal Cancer: Lessons from the Past Hope for the Future, United Medical Grand Rounds, United Memorial Medical Center, Batavia, NY, 6/25/2004 Polymorphism of Gemcitabine Metabolism, ASCO annual meeting, Chicago, IL, 6/3/2008 Poster Discussant for Pancreatic Cancer Abstracts, ASCO Annual Meeting, Chicago, IL, 6/4/2010 ASCO Oral Poster Discussion, ASCO, 6/2011 Translational Advances in Cancer, Udaipur, India, 12/18/2011 GI Cancers, ASCO, Chicago, IL, 6/1/2012 Javle M. ASCO - Discussant Oral Presentation Session, ASCO Annual Meeting, ASCO, 2013 ASCO Oral Poster Session: GI (Non-colorectal) Cancer, ASCO, Chicago, IL, 6/3/2013 Pancreatic and Biliary Cancers, Denali Oncology Conference, Wrangell, AK, 8/1/2013 Javle M. Highlights of the Day Session, ASCO Annual Meeting, ASCO 2013 Annual Meeting, 2014 Milind Javle, MD. Therapeutic Progress in Advanced Pancreatic Cancer, Phillips Gilmore Oncology Communications, Northside Hospital Department of Education, Atlanta, GA, 8/25/2018

Seminar Invitations from Other Institutions NCCN Occult Primary, National Comprehensive Cancer Network (NCCN), Philadelphia, PA, 9/28/2007 Future directions in pancreatic cancer, Vanderbilt Cancer Ctr, Nashville, TN, 10/5/2008 Update in upper gastrointestinal cancers, Cancer Summit, Hilton Head, SC, 7/24/2009 Grand Rounds - GI Cancers, Cleveland Clinic, Cleveland, OH, 9/6/2012

Lectureships and Visiting Professorships N/A

Other Presentations at State and Local Conferences Pancreatic Cancer: Challenging the Status Quo, The Division of Cancer Medicine and The Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2/28/2012 Javle MM. The Changing Spectrum of Biliary Cancer, The Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Division of Cancer Medicine Grand Rounds, Houston, TX, 2/25/2014 Milind Javle, MD. Systemic therapy for metastatic pancreas adenocarcinoma. New trends, 1st MD Anderson International Meeting in Gastrointestinal Oncology, UTMD Anderson, UTMD Anderson, Madrid, Spain, 11/29/2017

PROFESSIONAL MEMBERSHIPS/ACTIVITIES

Milind Javle, M.D.

of 24

Professional Society Activities, with Offices Held National and International

American Association for Cancer Research (AACR) Member, 2004-present

American Society of Clinical Oncology (ASCO) Member, 2004-present

Data Monitoring and Safety Committee, Ohio State University Cancer Center, Columbus, OH Reviewer, 2004-2007

Guidelines Panel, National Comprehensive Cancer Network (NCCN), Philadelphia, PA Member, 2004-present

American Society of Clinical Oncology (ASCO), Alexandria, VA Scientific Program Committee Member, 2007-present

Institutional Research Group, The University of Texas MD Anderson Cancer Center, Houston, TX

Member, 2008-present The University of Texas MD Anderson Cancer Center, Houston, TX

Senate Member, 2011-present Local/State

Harris County Medical Society, Houston, TX Member, 2005-present

The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, TX Associate Member, 2009-2010

UNIQUE ACTIVITIES 1. ASCO Scientific Program Committee: GI-Non colorectal track leader

2. ASCO 2008 Annual meeting- poster discussion session: co-chair

3. R21RCA135604A: BikDD nanoparticle for pancreatic cancer. Score 136, 9.3 percentile

4. 1R01CA152410-01A1: Targeting DNA repair in pancreatic cancer. Score: 32, 26 percentile

5. June 27, 2018: Medical Marvel Segment with Melissa Wilson on Fox 26 News. Live interview to discuss "Cholangiocarcinoma Study"

DATE OF LAST CV UPDATE

4/16/2019

curriculum vitae milind javle, m.d. · curriculum vitae milind javle, m.d. present title and...

Documents